The Florida Senate
BILL ANALYSIS AND FISCAL IMPACT STATEMENT
(This document is based on the provisions contained in the legislation as of the latest date listed below.)
Prepared By: The Professional Staff of the Committee on Health Policy
BILL: SB 890
INTRODUCER: Senator Yarborough
SUBJECT: Improving Screening for and Treatment of Blood Clots
DATE: March 10, 2025
ANALYST STAFF DIRECTOR REFERENCE ACTION
1. Looke Brown HP Pre-meeting
2. AHS
3. FP
I. Summary:
SB 890 amends and creates several sections of the Florida Statutes to:
• Specify that chronic critical illness and genetic predisposition for developing blood clots and
pulmonary embolisms are chronic diseases.
• Require the Department of Health (DOH) to create a blood clot and pulmonary embolism
registry (registry);
• Require specified training and protocols to screen a patient for the risk of blood clots,
pulmonary embolism, or deep vein thrombosis (DVT) when the patient is admitted to a
hospital or ambulatory surgical center (ASC) that provides specified services;
• Require certified nursing assistants (CNA) serving in a nursing home to receive training on
recognizing the signs and symptoms of a blood clot, pulmonary embolism, or DVT and
techniques for providing an emergency response;
• Require the Agency for Health Care Administration’s (AHCA) rules for assisted living
facilities (ALF) to include requirements for the identification of residents at risk for
developing blood clots and for the treating facility’s response protocols to ensure timely
treatment; and
• Require the AHCA to include training on the identification of and response to residents at
high risk of developing blood clots and pulmonary embolisms in the core training required
for all ALF administrators.
The bill provides an effective date of July 1, 2025.
II. Present Situation:
Blood Clots
Blood clotting, or coagulation, is an important process that prevents excessive bleeding when a
blood vessel is injured. Platelets (a type of blood cell) and proteins in plasma (the liquid part of
REVISED: BILL: SB 890 Page 2
blood) work together to stop the bleeding by forming a clot over the injury. Typically, the human
body will naturally dissolve the blood clot after the injury has healed.
Sometimes, however, blood clots form on the inside of vessels without an obvious injury or do
not dissolve naturally. These situations can be dangerous and require accurate diagnosis and
appropriate treatment.
Clots can occur in veins or arteries, which are vessels that are part of the body’s circulatory
system. While both types of vessels help transport blood throughout the body, they each function
differently. Veins are low-pressure vessels that carry deoxygenated blood away from the body’s
organs and back to the heart. An abnormal clot that forms in a vein may restrict the return of
blood to the heart and can result in pain and swelling as the blood gathers behind the clot.
DVT is a type of clot that forms in a major vein of the leg or, less commonly, in the arms, pelvis,
or other large veins in the body. In some cases, a clot in a vein may detach from its point of
origin and travel through the heart to the lungs where it becomes wedged, preventing adequate
blood flow. This is called a pulmonary (lung) embolism and can be extremely dangerous.
It is estimated that each year DVT affects as many as 900,000 people in the United States and
kills up to 100,000.
1
Blood Clots and Genetics
Thrombophilia is a medical term used to describe the condition where the blood has an increased
tendency to clot. There are many reasons why the blood can have this increased tendency.
Thrombophilia is usually categorized into two types–acquired and inherited. In acquired
thrombophilia the abnormal clotting is usually related to a specific cause, such as prolonged
periods of bed rest after surgery, trauma to the leg, or having cancer. People with inherited
thrombophilia tend to form clots due to a genetic predisposition inherited from their parents.
People with inherited thrombophilia may have a family history of relatives with abnormal or
excessive blood clotting.
Blood clotting proteins, like all proteins, are made by linking together a chain of chemicals
called amino acids. The order of the amino acids in the chain make up a specific protein; this
order is determined by genes. While there are a number of mutations that can cause inherited
thrombophilia, the most common deoxyribose nucleic acid (DNA) mutations are named
factor V Leiden and prothrombin G20210A.
2
Factor V Leiden
Human bodies produce a protein called factor V that helps blood clot. However, there are certain
individuals who have a DNA mutation in the gene used to make the factor V protein. These
individuals are said to have the “factor V Leiden” mutation.
1
American Society of Hematology, Blood Clots, available at https://www.hematology.org/education/patients/blood-clots,
(last visited March 7, 2025).
2
National Blood Clot Alliance, The Genetics of Thrombophilia, Elizabeth Varga, available at
https://www.stoptheclot.org/about-clots/thrombophilia/genetics-of-thrombophilia/, (last visited March 7, 2025). BILL: SB 890 Page 3
Normally the factor V protein is produced to help the blood clot and is produced in greater
amounts after a blood vessel is damaged. The amount of factor V protein produced is controlled
by other proteins, including protein C and protein S. Protein C and protein S combine to help
break up factor V, thus preventing it from being reused and clotting the blood.
When a person has factor V Leiden, the mutation causes the protein to be abnormally shaped.
This abnormal shape prevents it from being broken down properly by proteins C and S. Since the
factor V protein is not broken down, it is left in the blood for a longer period of time and
increases the tendency for clotting.
It is estimated that about five percent of Caucasians have factor V Leiden, and it is more
common in individuals of European ancestry. In the United States, approximately one to two
percent of African Americans, Hispanic Americans, and Native Americans also have the
mutation. Factor V Leiden is rare in people of Asian decent.
3
Prothrombin G20210A Mutation
All individuals make the prothrombin (also called factor two) protein that helps blood clot.
However, there are certain individuals who have a DNA mutation in the gene used to make
prothrombin called the prothrombin G20210A or the factor II mutation.
Normally, the prothrombin protein is produced to help the blood clot and is produced in greater
amounts after a blood vessel is damaged. People who have a mutation in the prothrombin gene
produce more prothrombin protein than is normal. Since there is more of the prothrombin protein
in the blood, this increases the tendency for clotting.
A change in the prothrombin gene is present in two to four percent of Caucasians and is more
common in individuals of European ancestry. In the United States, approximately 0.4 percent of
African Americans also have the mutation. Prothrombin G20210A mutation is rare in other
demographic groups.
Deep Vein Thrombosis
DVT occurs when a blood clot (thrombus) forms in one or more of the deep veins in the body,
usually in the legs. Deep vein thrombosis can cause leg pain or swelling. Sometimes there are no
noticeable symptoms.
Persons can get DVT if they have certain medical conditions that affect how the blood clots. A
blood clot in the legs can also develop if a person doesn’t move for a long time, e.g. sitting for an
extended period while traveling a long distance or when a person is on bed rest due to surgery,
an illness, or an accident.
Deep vein thrombosis can be serious because blood clots in the veins can break loose. The clots
can then travel through the bloodstream and get stuck in the lungs, blocking blood flow
(pulmonary embolism). When DVT and pulmonary embolism occur together, it’s called venous
thromboembolism (VTE).
3
Id. BILL: SB 890 Page 4
Many things can increase the risk of developing DVT. The more risk factors are involved, the
greater the risk of DVT. Risk factors for DVT include:
• Age. Being older than 60 increases the risk of DVT, but DVT can occur at any age.
• Lack of movement. Muscle contractions help blood flow. Sitting for a long time, such as
when driving or flying, increases the risk of DVT. So does long-term bed rest, which may
result from a lengthy hospital stay or a medical condition such as paralysis.
• Injury or surgery. Injury to the veins or surgery can increase the risk of blood clots.
• Pregnancy. Pregnancy increases the pressure in the veins in the pelvis and legs. The risk of
blood clots from pregnancy can continue for up to six weeks after a baby is born. People with
an inherited clotting disorder are especially at risk.
• Birth control pills (oral contraceptives) or hormone replacement therapy. Both can
increase the blood’s ability to clot.
• Being overweight or obese. Being overweight increases the pressure in the veins in the
pelvis and legs.
• Smoking. Smoking affects how blood flows and clots, which can increase the risk of DVT.
• Cancer. Some cancers increase substances in the blood that cause the blood to clot. Some
types of cancer treatment also increase the risk of blood clots.
• Heart failure. Heart failure increases the risk of DVT and pulmonary embolism.
• Inflammatory bowel disease. Crohn's disease or ulcerative colitis increase the risk of DVT.
• A personal or family history of DVT or pulmonary embolism. A person with a family
history of these conditions might be at greater risk of developing DVT.
• Genetics. Some people have DNA changes that cause the blood to clot more easily.
4
III. Effect of Proposed Changes:
SB 890 amends and creates multiple sections of the Florida Statutes to make changes related to
blood clots.
Section 1 of the bill amends the list of chronic diseases
5
in s. 385.102, F.S., to add “chronic
critical illness” and “genetic predisposition for developing blood clots and pulmonary
embolisms.” The bill also updates the term “chronic obstructive lung disease” to “chronic
obstructive pulmonary disease.”
Section 2 of the bill creates s. 385.213, F.S., to require the DOH to establish, or contract with a
recognized medical organization in Florida and its affiliated institutions, to establish a statewide
registry to ensure that blood clot and pulmonary embolism reports are maintained and available
for use in the course of research for the purpose of reducing morbidity and mortality. The bill
specifies that hospitals are immune from liability for having provided information to the DOH
for inclusion in the registry.
4
Mayo Clinic, Deep Vein Thrombosis, June 11, 2022, available at https://www.mayoclinic.org/diseases-conditions/deep-
vein-thrombosis/symptoms-causes/syc-20352557, (last visited March 7, 2025).
5
The list contains diseases that must be included as chronic diseases under ch. 385, F.S., but is not exclusive. BILL: SB 890 Page 5
The bill requires each facility licensed under chs. 395
6
or 408,
7
F.S., to report to the DOH the
following information for each instance of a blood clot, pulmonary embolism, or DVT identified
in a patient:
• The number of blood clots, pulmonary embolisms, and deep vein thromboses identified and
diagnosed.
• The age of the patient.
• The zip code of the patient.
• The sex of the patient.
• Whether the patient is a resident of a licensed nursing home or assisted living facility.
• Whether the blood clot, pulmonary embolism, or deep vein thrombosis was fatal.
• How the diagnosis was made, such as by using imaging modalities.
• The treatment that was recommended for the blood clot, pulmonary embolism, or deep vein
thrombosis, as applicable.
The bill allows the DOH, by rule, to further specify what information is to be provided.
The bill specifies that the DOH, or the contractor operating the registry, may use or publish
information from the registry only for the purpose of advancing medical research or medical
education in the interest of reducing morbidity or mortality, except that a de-identified summary
of the information contained in the registry may be released for general publication.
The bill also creates a public records exemption, making the records confidential and exempt, for
personal identifying information held in the registry, except that:
• Such information may be released with the express written consent of the person or his or her
legally authorized representative;
• The DOH or the contractor may contact individuals for the purpose of epidemiologic
investigation and monitoring, provided such information that is confidential is not further
disclosed; and
• The DOH may exchange data that includes personal identifying information with any other
governmental agency or the contractor for the purpose of medical or scientific research,
provided such governmental agency or contractor does not further disclose information that
is confidential and exempt.
The bill specifies that any funds appropriated for implementation of the registry must be used for
establishing, administering, compiling, processing, and providing biometric and statistical
analyses to the reporting facilities. Funds may also be used to ensure the quality and accuracy of
the information reported and to provide management information to the reporting facilities.
The bill allows the DOH, by rule, to classify facilities for purposes of reports made to the
registry and specify the content and frequency of the reports. In classifying facilities, the DOH
must exempt certain facilities from reporting blood clot and pulmonary embolism information
that was previously reported to the DOH or retrieved from existing state reports made to the
DOH or the AHCA.
6
Hospitals and ASCs.
7
The list of facility types licensed pursuant to ch. 408, F.S., is in s. 408.802, F.S. BILL: SB 890 Page 6
The bill also exempts any facility from reporting to the registry if the primary purpose of the
facility is to provide psychiatric care.
Section 3 of the bill creates s. 395.3042, F.S., to require hospitals and ASCs that provide
emergency room services, orthopedic services, pregnancy services, or cancer treatment, to
arrange for the rendering of appropriate medical attention for persons at risk for blood clots,
pulmonary embolisms, or DVT as follows:
• Upon admission to such a facility, a patient must be assessed for risk of blood clots,
pulmonary embolisms, and DVT using a nationally recognized risk assessment tool.
• The training of all staff in the facility must include continuing education annually on how to
recognize a blood clot, pulmonary embolism, or DVT.
• The facility must have established protocols for staff to ensure that patients diagnosed with a
life-threatening blood clot, pulmonary embolism, or DVT are assessed for various treatment
options.
• The facility must have an established policy in place requiring a follow-up for all orthopedic
patients who have undergone lower extremity or pelvic surgery, to occur within 60 days after
discharge.
• The facility must have procedures in place to provide ongoing blood clot risk assessment for
patients who are at high risk of developing blood clots, are pregnant, or are being treated for
cancer.
Section 4 amends s. 400.211, F.S., to require that a nursing home’s in-service training for CNAs
must include recognizing signs and symptoms of a blood clot, pulmonary embolism, or DVT and
techniques for providing emergency response. The bill requires that the identification of signs
and symptoms of a blood clot and how to assist with a response protocol must be included in the
required training a CNA must have in order for a registered nurse to delegate duties to him or
her.
Sections 5 and 6 amend ss. 429.41 and 429.52, F.S., to require rules regulating ALFs to include
standards for the identification of residents who are at risk for developing blood clots and the
treating facility’s response protocols to help ensure access to timely treatment, and to require
core training for ALF administrators to include identification of and responding to residents at
high risk of developing blood clots and pulmonary embolisms.
IV. Constitutional Issues:
A. Municipality/County Mandates Restrictions:
None.
B. Public Records/Open Meetings Issues:
Article I, Sectio 24(c), of the Florida Constitution requires that any law enacting a new
public records exemption contain “only exemptions from [public records and meetings
requirements], and shall relate to one subject.” Additionally, any law enacting a new
public records exemption “shall state with specificity the public necessity justifying the
exemption.” BILL: SB 890 Page 7
Section 2 of SB 890 creates a new public records exemption for records held in the blood
clot and pulmonary embolism registry. However, this public records exemption is created
within a bill that contains other items and does not relate only to that public records
exemption. Additionally, the bill does not specifically state the public necessity for the
public records exemption. As such, it is possible that the public records exemption
created by the bill may be found to be unconstitutionally enacted, should the bill be
enacted.
C. Trust Funds Restrictions:
None.
D. State Tax or Fee Increases:
None.
E. Other Constitutional Issues:
None.
V. Fiscal Impact Statement:
A. Tax/Fee Issues:
None.
B. Private Sector Impact:
SB 890 may have an indeterminate negative fiscal impact on hospitals and other facilities
that are require to report specified information to the registry created by the bill or adopt
new training, policies, protocols, or procedures as required by the bill.
C. Government Sector Impact:
SB 890 may have an indeterminate fiscal impact on the DOH related to establishing and
maintaining the registry required by the bill.
VI. Technical Deficiencies:
None.
VII. Related Issues:
Section 2 of SB 890 creates the blood clot and pulmonary embolism registry within the DOH.
The bill requires that all facilities licensed with the AHCA under ch. 408, F.S., provide specified
information to the DOH. However, the bill only exempts hospitals from liability for providing
such information. It may be advisable to extend liability protection to all facility types that are
required to provide information under the bill. Additionally, it is unclear how some facilities BILL: SB 890 Page 8
licensed under ch. 408, F.S., such as nurse registries and home medical equipment providers,
would be able to comply with the requirement to provide the specified information. The bill
allows the DOH, by rule, to classify and exempt certain facilities from the bill’s reporting
requirements, but it is unclear whether this rulemaking authority would be sufficient to allow the
DOH to exempt other types of facilities not listed in the bill.
Section 2 of the bill also specifies that any funds appropriated for the implementation of the
registry must be used for “establishing, administering, compiling, processing, and providing
biometric and statistical analyses to the reporting facilities.” Given the large quantity and the
multiple types of facilities required to report, it is unclear whether such reporting would be
practical.
Section 3 of the bill requires that certain hospitals and ASCs provide specified training and
create specified policies, protocols, and procedures related to blood clots, pulmonary embolisms,
and DVT. However, the bill does not specify the time frame in which such training, policies,
protocols, and procedures must be adopted. It may be advisable to allow hospitals and ASCs a
specific amount of time to put such training, policies, protocols, and procedures in place prior to
requiring them.
VIII. Statutes Affected:
This bill substantially amends the following sections of the Florida Statutes: 385.102, 400.211,
429.41, and 429.52.
This bill creates the following sections of the Florida Statutes: 385.213 and 395.3042.
IX. Additional Information:
A. Committee Substitute – Statement of Changes:
(Summarizing differences between the Committee Substitute and the prior version of the bill.)
None.
B. Amendments:
None.
This Senate Bill Analysis does not reflect the intent or official position of the bill’s introducer or the Florida Senate.